Article
Pharmacology & Pharmacy
Andrea Montesel, Claudio Bucolo, Ferenc B. Sallo, Chiara M. Eandi
Summary: This study reports the early efficacy and safety outcomes of treating nAMD with intravitreal injections of brolucizumab. The results showed that brolucizumab was highly effective in restoring anatomy and stabilizing visual acuity, but its safety profile requires further evaluation.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Ophthalmology
Joshua H. Uhr, Philip P. Storey, Brandon Kuley, Samir N. Patel, Turner D. Wibbelsman, Maitri Pancholy, Marc J. Spirn
Summary: The study showed that endophthalmitis after anti-vascular endothelial growth factor injection does not significantly worsen the underlying exudative disease process, providing relative stability. Continued injections may be necessary in certain cases, especially for patients with choroidal neovascularization. Further research is needed to elucidate the mechanism and develop treatment strategies for exudative macular diseases.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2021)
Article
Chemistry, Medicinal
Ersilia Lucenteforte, Marco Finocchietti, Antonio Addis, Mauro Tettamanti, Monica Varano, Mariacristina Parravano, Gianni Virgili
Summary: This study aimed to describe the polytherapy and multimorbidity pattern of patients receiving anti-VEGF and dexamethasone drugs for the treatment of retinal conditions. The results revealed that patients receiving intravitreal injections have a high prevalence of multimorbidity and polytherapy, leading to a significant burden of care.
Article
Pharmacology & Pharmacy
Yun Zhang, Sheng Gao, Xun Li, Xi Huang, Yi Zhang, Tiancong Chang, Zhaolun Cai, Meixia Zhang
Summary: The study evaluated the efficacy and safety of anti-VEGF monotherapy in nAMD patients and concluded that brolucizumab, aflibercept, and ranibizumab are the ideal treatment regimens.
FRONTIERS IN PHARMACOLOGY
(2021)
Article
Medicine, General & Internal
Koji Tanaka, Hiroyuki Shimada, Ryusaburo Mori, Yorihisa Kitagawa, Hajime Onoe, Kazuki Tamura, Hiroyuki Nakashizuka
Summary: During the COVID-19 pandemic, intravitreal injections with patients wearing masks can effectively reduce the risk of endophthalmitis. A retrospective study found that even during the pandemic, implementing basic infection prophylactic measures such as face draping and povidone-iodine irrigation can maintain a very low incidence of endophthalmitis after intravitreal injection.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Medicine, Research & Experimental
Lei Xi
Summary: Ocular ischemia is a vision-threatening disease associated with various ocular diseases. This study investigated the effects of pigment epithelium derived factor (PEDF) and anti-vascular endothelial growth factor (anti-VEGF) therapy, as well as their combined use, on an ex vivo ischemic rat eye model. The results showed that the combination of PEDF and anti-VEGF significantly reduced the staining intensity of VEGF and GFAP, and decreased the number of TUNEL-positive nuclei, indicating its potential as a therapeutic strategy for ischemic retinal and choroidal diseases.
BIOMEDICINE & PHARMACOTHERAPY
(2022)
Article
Biochemistry & Molecular Biology
Rajya L. Gurung, Liesel M. FitzGerald, Ebony Liu, Bennet J. McComish, Georgia Kaidonis, Bronwyn Ridge, Alex W. Hewitt, Brendan J. Vote, Nitin Verma, Jamie E. Craig, Kathryn P. Burdon
Summary: This study identified genetic determinants associated with anti-VEGF treatment response in patients with DME through a genome-wide association study. Multiple genetic loci were found to predict treatment outcomes, potentially leading to personalized treatment approaches for managing DME.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2022)
Review
Biochemistry & Molecular Biology
Akiyoshi Uemura, Yoko Fukushima
Summary: Rho GTPases, especially RhoJ, play essential roles in regulating cell migration and junctions in vascular endothelial cells, affecting vascular formation and permeability. RhoJ, enriched in angiogenic ECs, induces actin depolymerization by competing with Cdc42 for common effector proteins, thus influencing cytoskeletal rearrangements.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Ophthalmology
Richard Gale, Maria Pikoula, Aaron Y. Lee, Spiros Denaxas, Catherine Egan, Adnan Tufail, Paul Taylor
Summary: Real-world data from 27 National Health Service Trusts in the UK showed that anti-vascular endothelial growth factor was more effective in treating macular oedema secondary to branch retinal vein occlusion compared to intravitreal dexamethasone, with sustained visual acuity improvements. Patients in the anti-VEGF group had higher visual acuity improvements at different time points, and the treatment burden reduced over time.
BRITISH JOURNAL OF OPHTHALMOLOGY
(2021)
Review
Medicine, General & Internal
Ryo Terao, Ryosuke Fujino, Tazbir Ahmed
Summary: Retinal occlusive diseases, including retinal artery occlusion and retinal vein occlusion, are common causes of visual impairment. These diseases have different pathophysiologies and require different treatment approaches. Prompt examinations and interventions for systemic vascular diseases are necessary for patients with retinal artery occlusion, which is mainly caused by thromboembolism. Retinal vein occlusion, characterized by retinal hemorrhage and ischemia, can lead to visual impairment through various complications. While anti-vascular endothelial growth factor therapy is the first-line treatment for retinal vein occlusion, other treatment protocols and new therapeutic options are under investigation.
JOURNAL OF CLINICAL MEDICINE
(2022)
Article
Ophthalmology
Tyler E. Greenlee, Victoria Y. Wang, Hannah Kang, Marc E. Ohlhausen, Andrew X. Chen, Grant L. Hom, Thais F. Conti, Isaac Briskin, Amy S. Babiuch, Rishi P. Singh
Summary: The study found that patients with neovascular age-related macular degeneration who experience treatment lapses may exhibit significant increase in central subfield thickness and loss in visual acuity. Although macular thickness normalizes on resumption of treatment, their decline in visual acuity does not recover within 12 months of follow-up.
RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES
(2021)
Review
Medicine, General & Internal
Yuzhi Bao, Xiaolei Lu, Yuwei Zhou
Summary: This study aimed to compare the efficacy and safety of methotrexate plus anti-VEGF therapy in the treatment of DME, with the hypothesis that combined therapies would provide better therapeutic benefits compared to single method.
Article
Endocrinology & Metabolism
Jingwei Jiang, John J. Reho, Sajag Bhattarai, Ioana Cherascu, Adam Hedberg-Buenz, Kacie J. Meyer, Fariba Tayyari, Adam J. Rauckhorst, Deng Fu Guo, Donald A. Morgan, Eric B. Taylor, Michael G. Anderson, Arlene Drack, Kamal Rahmouni
Summary: The study demonstrates that deficiency of BBSome in endothelial cells leads to endothelial dysfunction, increased body weight, abnormal hepatic lipid metabolism, and structural and functional abnormalities in the retina.
MOLECULAR METABOLISM
(2021)
Article
Neurosciences
Jeremie Canonica, Richard Foxton, Marina Garcia Garrido, Cheng-Mao Lin, Sabine Uhles, Sumathi Shanmugam, David A. Antonetti, Steven F. Abcouwer, Peter D. Westenskow
Summary: Clinical trials have shown that faricimab, a medication targeting angiopoietin-2 (Ang-2) and vascular endothelial growth factor (VEGF-A), provides effective and long-lasting treatment for neovascular age-related macular degeneration and diabetic macular edema. However, the mechanism behind these results and the role of Ang-2 inhibition require further investigation.
FRONTIERS IN CELLULAR NEUROSCIENCE
(2023)
Article
Ophthalmology
Meiaad Khayat, Jennifer Perais, David M. Wright, Michael Williams, Noemi Lois
Summary: The study aimed to evaluate anatomic-functional associations at sites of retinal lesions in RVO patients. The results showed decreased retinal sensitivity at sites of RVO lesions, with impaired function in ischemic areas not recovering after treatment and even worsened with reperfusion.
INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
(2021)